Lyophilized Injectables Market Set to Hit USD 4,978.3 Million by 2030, Growing at 5.6% CAGR

Posted on 2024-04-16 by MarketDigits in Healthcare // 0 Comments

Richmond, United States, 2024-Apr-16 — /EPR Network/ —

The Lyophilized Injectables Market, valued at USD 3,365.4 Million in 2022, is projected to reach USD 4,978.3 Million by 2030, with a growth rate of 5.6% during the forecast period from 2023 to 2030.

The lyophilized injectable market has experienced significant growth in recent years, driven by various factors such as the rising prevalence of chronic diseases, technological advancements, and increasing demand for convenient drug delivery methods. This blog explores the current size of the lyophilized injectable market and provides insights into its growth trajectory.

Download the Sample –
https://www.marketdigits.com/request/sample/3589

Major vendors in the global Lyophilized Injectables market:

Aristopharma Ltd.
B. Braun SE
Cirondrugs
CordenPharma International
Nipro Europe Group Companies (Nipro Corporation)
Pace Biotech
Protech Telelinks
SCHOTT Pharma (SCHOTT AG)
Unison Chemical Works
Weefsel Pharma

Market Size Overview

The global lyophilized injectable market size is estimated to be valued at approximately USD X billion in 2022. This market encompasses a wide range of pharmaceutical products that undergo lyophilization, a process of freeze-drying to enhance their stability, prolong shelf life, and facilitate reconstitution before administration.

Request for Discount
https://www.marketdigits.com/request/discount/3589

Factors Driving Market Growth

Rising Demand for Biologics: The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders has led to a growing demand for biologic drugs, many of which are formulated as lyophilized injectables. Biologics require specialized storage and handling conditions to maintain their stability, making lyophilization an attractive option for drug manufacturers.
Technological Advancements: Ongoing advancements in lyophilization technology have improved the efficiency and scalability of the lyophilization process, reducing production costs and expanding the range of drugs that can be formulated as lyophilized injectables. Innovations such as improved lyophilization cycles, advanced equipment, and novel excipients have contributed to market growth.
Preference for Parenteral Administration: Lyophilized injectables offer several advantages over other dosage forms, particularly for drugs that require parenteral administration. Lyophilized formulations are easy to transport, have a longer shelf life compared to liquid formulations, and allow for precise dosing and reconstitution at the point of care, making them suitable for use in hospital settings and emergency situations.
Growing Pipeline of Biopharmaceuticals: The increasing number of biopharmaceuticals in the drug development pipeline, including monoclonal antibodies, vaccines, and cell therapies, is driving demand for lyophilized injectables. These complex biologics often require lyophilization to maintain their stability and bioactivity during storage and transport.

Regional Insights

The lyophilized injectable market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America currently dominates the market, followed by Europe, due to the presence of a well-established pharmaceutical industry, high healthcare expenditure, and a large patient population with chronic diseases. However, the Asia Pacific region is expected to witness the fastest growth in the coming years, driven by factors such as increasing healthcare infrastructure development, rising investment in research and development, and growing adoption of biopharmaceuticals.

Major Segmentations Are Distributed as follows:

By Packaging Type
- Single-use Vials
- Point-of-care Reconstitution
- Specialty Packaging
By Delivery Type
- Prefilled Diluent Syringes
- Proprietary Reconstitution Devices
- Single-step Devices
- Multi-step Devices
By Indication
- Autoimmune Diseases
- Infectious Diseases
- Metabolic Conditions
- Others
By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
By Region
- North America
  - US
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Colombia
  - Chile
  - Peru
  - Rest of Latin America
- Europe
  - UK
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - BENELUX
  - CIS & Russia
  - Nordics
  - Austria
  - Poland
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - Thailand
  - Indonesia
  - Malaysia
  - Vietnam
  - Australia & New Zealand
  - Rest of Asia Pacific
- Rest of the World
  - Saudi Arabia
  - UAE
  - South Africa
  - Nigeria
  - Egypt
  - Israel
  - Turkey

Recent Developments

December 6, 2023, SCHOTT Pharma has achieved a significant milestone as it becomes a publicly traded company. Included among the top 160 shares on the Frankfurt stock exchange, the SDAX index consists of the 70 largest and most liquid companies, trailing the DAX and MDAX in market capitalization. The primary factor determining the weight of SDAX shares is market capitalization based on free float, with SCHOTT Pharma accounting for approximately 23%. The company officially entered the public market on September 28 this year on the Frankfurt Stock Exchange, marking the most substantial German IPO of 2023. SCHOTT Pharma intends to unveil its full-year financial results during a press conference scheduled for January 26, 2024.

Buy Now :-
https://www.marketdigits.com/checkout/3589?lic=s

Conclusion

The lyophilized injectable market is witnessing steady growth globally, driven by factors such as the rising prevalence of chronic diseases, technological advancements, and increasing demand for biologic drugs. With the advantages of enhanced stability, prolonged shelf life, and convenient reconstitution, lyophilized injectables have become a preferred dosage form for a wide range of pharmaceutical products.

Matched content

Editor’s pick